Membership Directory - Corporate
DirectSeq Biosciences, Inc. (DSI)
About
DirectSeq Biosciences, Inc. (DSI), a pioneering biotech startup, is thrilled to announce the launch of our direct RNA sequencing business. We lead the genomic industry with our state-of-the-art mass spectrometry (MS)-based sequencing technologies, enabling comprehensive sequencing of RNA modifications and decoding the complete RNA sequence.
Our groundbreaking technologies go beyond the limitations of conventional high-throughput sequencing methods. In addition to decoding the four canonical nucleotides, we can identify over 170 different types of modified nucleotides in RNA. Developed at New York Tech, our technologies have received significant support, including over $6 million in research grants from the National Institutes of Health (NIH), including prestigious Center and R01 grants.
Our customer base encompasses researchers in academia, biopharmaceutical companies developing RNA-based vaccines and therapeutics, FDA and federal agencies overseeing RNA drugs, as well as clinics focused on RNA-based diagnosis and treatment.
Our groundbreaking technologies go beyond the limitations of conventional high-throughput sequencing methods. In addition to decoding the four canonical nucleotides, we can identify over 170 different types of modified nucleotides in RNA. Developed at New York Tech, our technologies have received significant support, including over $6 million in research grants from the National Institutes of Health (NIH), including prestigious Center and R01 grants.
Our customer base encompasses researchers in academia, biopharmaceutical companies developing RNA-based vaccines and therapeutics, FDA and federal agencies overseeing RNA drugs, as well as clinics focused on RNA-based diagnosis and treatment.
